Major Publications
-
2021/5/21
Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706)
The phase III ACTIVE study (CTONG1706) aimed to evaluate apatinib+gefitinib as first-line treatment for advanced EGFR-mutant NSCLC. 313 patients were randomized to receive apatinib+gefitinib or placebo+apatinib. Apatinib+gefitinib as first-line therapy demonstrated superior PFS. Combination therapy brought more adverse events but did not interfere quality of life.
See the original article:
J Thorac Oncol. 2021 May 24;S1556-0864(21)02177-8.
https://pubmed.ncbi.nlm.nih.gov/34033974/
-
2021/5/15
Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy
51 patients (test cohort: 25, expansion cohort:26) were treated with decitabine plus camrelizumab. The ORR was 52% and 68% in the test and expansion cohort, respectively. Median PFS was 20.0 and 21.6 months, respectively, which was significantly longer than that achieved with prior anti-PD-1 monotherapy.
See the original article:
Clinical Cancer Research 2021 May 15;27(10):2782-2791; doi: 10.1158/1078-0432.CCR-21-0133
https://clincancerres.aacrjournals.org/content/27/10/2782.full-text.pdf
-
2021/4/20
Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report
The effect of immunotherapy in patients with recurrent UTUC still lacks specific evidence. Herein, our case indicated that Camrelizumab is a promising agent in treating locally advanced and recurrent UTUC patients with poor performance status and impairted renal function.
See the original article:
Transl Androl Urol. 2021 Apr. 10(4):1821-1826. doi: 10.21037/tau-21-268
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100841/
-
2021/4/1
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Sixty-one patients with relapsed/refractory cHL were randomized 1:2 to receive either camrelizumab monotherapy or camrelizumab combined with decitabine. Decitabine-plus-camrelizumab results in longer PFS compared with camrelizumab alone in patients with relapsed/refractory cHL.
See the original article:
Journal for ImmunoTherapy of Cancer 2021;9:e002347. doi:10.1136/jitc-2021-002347
https://jitc.bmj.com/content/jitc/9/4/e002347.full.pdf
-
2021/3/1
Long-term results of phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer
The long-term efficacy and safety of apatinib in 20 patients with RAIR-DTC in a phase II study was reported after a median follow-up of 42.4 months. The ORR and DCR was 80% and 95%. The median PFS was 18.4 months and median OS was 51.6 months.
See the original article:
The Journal of Clinical Endocrinology & Metabolism, 26 March 2021;dgab196. doi: 10.1210/clinem/dgab196
https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgab196/6189101
-
2021/2/5
Primary Hepatic Squamous Cell Carcinoma With MSI-H Shows Good Response to PD-1 Inhibitor as Adjuvant Therapy
Primary hepatic squamous cell carcinoma (SCC) is a rare and highly aggressive liver cancer, with no effective treatment. This paper reports on a case of primary hepatic SCC following resection that responded dramatically to a PD-1 inhibitor camrelizumab, with tumor-free survival of 14 months to date.
See the original article:
Hepatology. 2021 Feb 5. doi: 10.1002/hep.31737. Online ahead of print.
https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.31737